Literature DB >> 16955819

Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002).

Bernard Séguin1, M Faulkner Besancon, Jennifer L McCallan, Loralei L Dewe, Matthew C Tenwolde, Emily K Wong, Michael S Kent.   

Abstract

The objectives of this study were to determine local recurrence rate, clinical outcome, and prognostic value of the number of argyrophylic nucleolar organizer regions (AgNORs), presence of proliferating cell nuclear antigen (PCNA), and number of Ki-67-positive nuclei after incomplete surgical excision of canine cutaneous grade II mast cell tumors (MCTs). This retrospective study included 30 MCTs in 28 dogs. Medical records were examined and follow-up information was obtained from owners and referring veterinarians. Only cases in which excision was incomplete and no anvcillary therapy (other than prednisone) for MCT was given were included. Paraffin-embedded tumor tissues were retrieved for AgNORs, PCNA, and Ki-67 staining. Median follow-up time was 811.5 days. Seven (23.3%) tumors recurred locally. Median time to local recurrence was not reached with a mean of 1,713 days. The estimated proportions of tumors that recurred locally at 1, 2, and 5 years were 17.3, 22.1, and 33.3%, respectively. Eleven (39.3%) dogs developed MCTs at other cutaneous locations. Median progression-free survival was 1,044 days. Median overall survival was 1,426 days. The combination of Ki-67 and PCNA scores was prognostic for local recurrence (P = .03) and development of local recurrence was prognostic for decreased overall survival (P = .04). Results suggest that a minority of incompletely excised MCTs recur. Therefore, ancillary local therapies may not always be necessary. However, local recurrence can negatively affect survival of the affected dogs. Cellular proliferation indices may indicate the likelihood of MCT recurrence after incomplete excision.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16955819     DOI: 10.1892/0891-6640(2006)20[933:rrcoac]2.0.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  10 in total

1.  The effect of prednisone on histologic and gross characteristics in canine mast cell tumors.

Authors:  Ken J Linde; Stephen L Stockdale; Michael B Mison; James A Perry
Journal:  Can Vet J       Date:  2021-01       Impact factor: 1.008

2.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

3.  A Novel Imaging System Distinguishes Neoplastic from Normal Tissue During Resection of Soft Tissue Sarcomas and Mast Cell Tumors in Dogs.

Authors:  Suzanne Bartholf DeWitt; William C Eward; Cindy A Eward; Alexander L Lazarides; Melodi Javid Whitley; Jorge M Ferrer; Brian E Brigman; David G Kirsch; John Berg
Journal:  Vet Surg       Date:  2016-06-09       Impact factor: 1.495

4.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

5.  RNAScope in situ Hybridization as a Novel Technique for the Assessment of c-KIT mRNA Expression in Canine Mast Cell Tumor.

Authors:  Davide De Biase; Francesco Prisco; Giuseppe Piegari; Arianna Ilsami; Ilaria d'Aquino; Valeria Baldassarre; Federica Zito Marino; Renato Franco; Serenella Papparella; Orlando Paciello
Journal:  Front Vet Sci       Date:  2021-02-16

6.  Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone.

Authors:  Thais Rodrigues Macedo; Genilson Fernandes de Queiroz; Thaís Andrade Costa Casagrande; Pâmela Almeida Alexandre; Paulo Eduardo Brandão; Heidge Fukumasu; Samanta Rios Melo; Maria Lucia Zaidan Dagli; Ana Carolina B C Fonseca Pinto; Julia Maria Matera
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

7.  Outcomes of adjunctive radiation therapy for the treatment of mast cell tumors in dogs and assessment of toxicity: A multicenter observational study of 300 dogs.

Authors:  Sarah L Mason; Charles Pittaway; Begona Pons Gil; Onne-Marju Russak; Katie Westlake; Davide Berlato; Jérôme Benoit; Joanna Morris; Jane Margaret Dobson
Journal:  J Vet Intern Med       Date:  2021-10-21       Impact factor: 3.333

8.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07

9.  Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.

Authors:  Pamela D Jones; Justine E Campbell; Graham Brown; Chad M Johannes; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-12-22       Impact factor: 3.175

Review 10.  Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal.

Authors:  Michael Willmann; Vilma Yuzbasiyan-Gurkan; Laura Marconato; Mauro Dacasto; Emir Hadzijusufovic; Olivier Hermine; Irina Sadovnik; Susanne Gamperl; Mathias Schneeweiss-Gleixner; Karoline V Gleixner; Thomas Böhm; Barbara Peter; Gregor Eisenwort; Richard Moriggl; Zhixiong Li; Mohamad Jawhar; Karl Sotlar; Erika Jensen-Jarolim; Veronika Sexl; Hans-Peter Horny; Stephen J Galli; Michel Arock; David M Vail; Matti Kiupel; Peter Valent
Journal:  Front Vet Sci       Date:  2021-12-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.